Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics


Arcus Biosciences, Inc. (RCUS)

Today's Latest Price: $37.00 USD

0.97 (2.69%)

Updated Jan 27 7:45am

Add RCUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

RCUS Stock Summary

  • The ratio of debt to operating expenses for Arcus Biosciences Inc is higher than it is for about merely 0.52% of US stocks.
  • RCUS's price/sales ratio is 30.07; that's higher than the P/S ratio of 92.01% of US stocks.
  • Revenue growth over the past 12 months for Arcus Biosciences Inc comes in at 1,041.81%, a number that bests 99.21% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Arcus Biosciences Inc, a group of peers worth examining would be MORF, XENE, VYGR, NTLA, and FULC.
  • Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arcusbio.com.

RCUS Stock Price Chart Interactive Chart >

Price chart for RCUS

RCUS Price/Volume Stats

Current price $37.00 52-week high $40.01
Prev. close $36.03 52-week low $8.55
Day low $37.00 Volume 409
Day high $37.00 Avg. volume 531,789
50-day MA $30.05 Dividend yield N/A
200-day MA $25.70 Market Cap 2.40B

Arcus Biosciences, Inc. (RCUS) Company Bio


Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.


RCUS Latest News Stream


Event/Time News Detail
Loading, please wait...

RCUS Latest Social Stream


Loading social stream, please wait...

View Full RCUS Social Stream

Latest RCUS News From Around the Web

Below are the latest news stories about Arcus Biosciences Inc that investors may wish to consider to help them evaluate RCUS as an investment opportunity.

Arcus Biosciences: Highly Valued Even Without A Phase 3 Study

Arcus Biosciences (RCUS), founded by Terry Rosen who we discussed briefly in a previous article, has a $2.4bn market cap based on a sophisticated pipeline of mid-stage cancer molecules, collaboration deals with Gilead (GILD) for 10 years, and AstraZeneca (AZN), and nearly $785mn in cash reserves that could be the...

Avisol Capital Partners on Seeking Alpha | January 17, 2021

Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).

Yahoo | January 15, 2021

Affimed (AFMD) Catches Eye: Stock Jumps 8.8%

Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Yahoo | January 14, 2021

Barclays Stick to Their Buy Rating for Arcus Biosciences Inc By Investing.com

Barclays Stick to Their Buy Rating for Arcus Biosciences Inc

Investing.com | January 12, 2021

bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

Yahoo | January 12, 2021

Read More 'RCUS' Stories Here

RCUS Price Returns

1-mo 29.69%
3-mo 57.98%
6-mo 88.01%
1-year 282.63%
3-year N/A
5-year N/A
YTD 42.53%
2020 157.03%
2019 -6.22%
2018 N/A
2017 N/A
2016 N/A

Continue Researching RCUS

Want to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:

Arcus Biosciences Inc (RCUS) Stock Price | Nasdaq
Arcus Biosciences Inc (RCUS) Stock Quote, History and News - Yahoo Finance
Arcus Biosciences Inc (RCUS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8176 seconds.